Evogene Ltd. (EVGN) vs Processa Pharmaceuticals, Inc. (PCSA)
A side-by-side comparison of Evogene Ltd. and Processa Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EVGN
Evogene Ltd.
$0.44HealthcareDelayed quote: Oct 6, 2026, 1:45 PM EDT
PCSA
Processa Pharmaceuticals, Inc.
$1.52HealthcareDelayed quote: Oct 6, 2026, 1:54 PM EDT
Total return — EVGN vs PCSA
growth of $100 · dividends reinvested · last 10yEVGN -99.4% (-39.7%/yr)PCSA -99.9% (-48.6%/yr)EVGN compounded faster over this window
EVGN PCSA
EVGN vs PCSA: by the numbers
- •PCSA is the larger company ($4M vs $4M market cap).
- •Both run net losses; PCSA's is the smaller (0.00% vs -694.19% net margin).
Metrics side by side
Valuation
| Metric | EVGN | PCSA |
|---|---|---|
| P/S ratio | 2.90 | N/A |
Profitability
| Metric | EVGN | PCSA |
|---|---|---|
| Gross margin | -6.25% | 0.00% |
| Operating margin | -364.24% | 0.00% |
| Net margin | -694.19% | 0.00% |
| ROIC | -130.12% | N/A |
Growth (annualized)
| Metric | EVGN | PCSA |
|---|---|---|
| Revenue CAGR (5Y) | 2.86% | N/A |
| Total return CAGR (5Y) | -56.46% | -79.32% |
Frequently asked
- How have EVGN and PCSA total returns compared?
- Over the past 10 years, EVGN delivered -39.70% and PCSA delivered -48.59% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.